Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe page has undergone significant content removal regarding the details of a Phase 1/2 study for metastatic melanoma, including specific inclusion and exclusion criteria, as well as the study's goals and design. The only notable addition is the mention of 'Metastatic Melanoma' and a new revision number.SummaryDifference31%
- Check67 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check110 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.